Sling vs No Sling After Reverse Total Shoulder Arthroplasty

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study involves patients who will be undergoing a reverse total shoulder replacement at Duke University. 100 eligible will be randomly assigned into one of two groups, a sling or no sling group. Patients in the sling group will wear a sling for three weeks after their surgery while the no sling group will only wear a sling three days after their surgery. Patients will follow their doctors normal follow up visit schedule after surgery, with visits at 2 weeks, 6 weeks, 3 months, 6 months, 1 year, and 2 years.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:

• Patient is scheduled to undergo a primary reverse shoulder arthroplasty procedure

• Patient voluntarily consents to participate in the study and has the mental and physical ability to participate in the study, fill out subjective questionnaires, return for follow-up visits, and comply with prescribed post-operative physical therapy

• Patient meets indications for primary reverse shoulder arthroplasty for the following diagnosis

• Rotator cuff arthropathy

• Glenohumeral arthritis

• Patient is between 18-100 years old

• Patient is English speaking

Locations
United States
North Carolina
Duke University
RECRUITING
Durham
Contact Information
Primary
Caroline Questell, BSN
caroline.darragh@duke.edu
919-613-3670
Time Frame
Start Date: 2023-12-07
Estimated Completion Date: 2028-12
Participants
Target number of participants: 100
Treatments
No_intervention: Sling
Participants in the sling group will wear a sling according to current standard of care: 3 weeks postoperatively (2 weeks all the time, 3rd week at night and while in the community)
Experimental: No Sling
Participants in the no sling group will only wear a sling for three days postoperatively
Related Therapeutic Areas
Sponsors
Leads: Duke University

This content was sourced from clinicaltrials.gov